天眩清治疗眩晕、耳鸣的临床观察

目的 观察天眩清注射液对周围性眩晕、神经性耳鸣的治疗效果。方法 眩晕患者120例，耳鸣患者80例，各随机分为实验组及对照组，按观察项目、评定标准进行系列临床观察。结果 两实验组病例中，眩晕者总有效率93．3％，耳鸣者总有效率77．5％。结论 天眩清注射液对周围性眩晕、神经性耳鸣有显著疗效，为一种安全有效的制剂。     

RP-HPLC测定天麻中天麻素的含量

目的 建立RP-HPLC测定天麻中天麻素含量的分析方法。方法 优化药材的提取及色谱的分析方法得分离良好的色谱图,外标法定量。色谱柱:Hypersil ODS色谱柱(4.6×250 mm);流动相:甲醇-0.1％冰醋酸水溶液(5:95);检测波长:270 nm。结果 色谱图中12个峰均可用其进行准确定量,其中天麻素含量测定的线性范围为0.60~2.41μg(r=0.999 9),平均加样回收率为97.85％,RSD=1.17％(n=5)。结论 本方法简便,准确,重现性好,可用于天麻中天麻素的含量测定,同时也可用于其它水溶性成分的定量。     

天银胶囊的制备及质量标准研究

目的:制备天银胶囊并建立其质量标准。方法:采用醇提工艺制备本品;对本品的薄层(TLC)鉴别、水分、崩解时限等各项指标进行研究,并以高效液相色谱法测定方中天麻素的含量。结果:TLC斑点清晰,分离度好。样品进样量在0.0992～3.1744μg范围内与峰面积积分值呈良好线性关系(r=0.9999);平均回收率为96.94%,RSD=1.35%(n=9)。结论:该制备工艺合理可行,质量标准全面可靠。     

HPLC法测定舒乐脑心通颗粒中天麻素的含量

目的:建立以高效液相色谱法测定舒乐脑心通颗粒中天麻素含量的方法。方法:色谱柱为Hypersil ODS(250mm×4·0mm,5μm),流动相为乙腈-0·05%磷酸溶液(2∶98),流速为1mL·min-1,检测波长为220nm。结果:天麻素进样量在0·1~2·0μg范围内与峰面积积分值呈良好的线性关系(r=1·0000);平均加样回收率为96·6%,RSD=0·80%(n=6)。结论:本法简便、快速、重现性好,可用于舒乐脑心通颗粒的质量控制。     

天麻素片溶出度测定方法研究

目的:建立天麻素片的溶出度测定方法。方法:采用紫外分光光度法测定天麻素片的溶出度。以水为溶剂,用溶出度测定法第一法,转速为50转/min,采用样品自身对照,检测波长为220nm。结果:天麻素线性关系较好(r=0.9999)。结论:该法灵敏、可靠、快速、简便,可用于天麻素片的溶出度测定。     

头风宁滴丸的质量标准研究

目的：建立头风宁滴丸的质量标准。方法：采用薄层色谱法进行定性鉴别,用高效液相色谱法测定滴丸中天麻素的含量,以乙腈-0.2%磷酸为流动相,梯度洗脱,流速：检测波长220 nm,柱温30℃。结果：薄层色谱检出白芷药材,天麻素在0.233-2.33 g范围内具有良好的线性关系,平均加样回收率为100.28%,RSD为2.26%（n=6）。结论：定性、定量方法简便、可靠、准确,可作为头风宁滴丸的质量控制方法。     

天麻有效成分提取工艺研究

目的:考察不同条件下天麻素的提取情况。方法:采用正交试验法,以提取液中天麻素的含量为指标优选提取工艺条件。结果:提取的最佳条件为选用6倍药材量的600 ml/L乙醇提取3次,每次1.5 h。     

天麻素联合黛力新治疗更年期焦虑状态疗效观察

目的探讨天麻素联合黛力新治疗更年期焦虑状态的治疗效果。方法采用汉密尔顿焦虑量表对前来就诊的更年期妇女（年龄45～55岁）进行测试。量表分值在14分以上的156例患者随机分成治疗组与对照组。治疗组使用天麻素联合黛力新治疗，对照组单用黛力新治疗。结果治疗组总有效率92．30％，对照组总有效率为64．10％，差异具有统计学意义，治疗组治疗后焦虑量表分值平均（7．10±2．02）分，对照组平均（12．94±1．69）分，差异具有统计学意义。结论天麻素对改善更年期焦虑状态有明显疗效。     

Protective effect of gastrodin on bile duct ligation-induced hepatic fibrosis in rats

Gastrodin has been showed to possess many beneficial physiological functions, including protection against inflammation and oxidation and apoptosis. Studies showed inflammation and oxidation play important roles in producing liver damage and initiating hepatic fibrogenesis. However, it has not been reported whether gastrodin has a protective effect against hepatic fibrosis or not. This is first ever made attempts to test gastrodin against liver fibrosis in bile duct ligation (BDL) rats. The aim of the present study is to evaluate the effect of gastrodin on BDL-induced hepatic fibrosis in rats. BDL rats were divided into two groups, BDL alone group, and BDL-gastrodin group treated with gastrodin (5 mg/ml in drinking water). The effects of gastrodin on BDL-induced hepatic injury and fibrosis in rats were estimated by assessing serum, urine, bile and liver tissue biochemistry followed by liver histopathology (using hematoxylin & eosin and sirius red stain) and hydroxyproline content measurement. The results showed that gastrodin treatment significantly reduced collagen content, bile duct proliferation and parenchymal necrosis after BDL. The serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) decreased with gastrodin treatment by 15.1 and 23.6 percent respectively in comparison to BDL group did not receive gastrodin. Gastrodin also significantly increased the level of serum high density lipoprotein (HDL) by 62.5 percent and down-regulated the elevated urine total bilirubin (TBIL) by 56.5 percent, but had no effect on total bile acid (TBA) in serum, bile and liver tissues. The immunohistochemical assay showed gastrodin remarkably reduced the expressions of CD68 and NF-κB in BDL rats. Hepatic SOD levels, depressed by BDL, were also increased by gastrodin by 8.4 percent. In addition, the increases of hepatic MDA and NO levels in BDL rats were attenuated by gastrodin by 31.3 and 38.7 percent separately. Our results indicate that gastrodin significantly attenuated the severity of BDL-induced hepatic injury and fibrosis by attenuating oxidative stress and inflammation. Taken together, these findings suggest that gastrodin might be an effective antifibrotic drug in cholestatic liver disease.